Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapu003 IV dose-escalation study in advanced breast cancer and other mTOR-sensitive solid tumors
ACTRN12625001083482Phase 2Recruiting
- Sponsor
- iNGENū CRO
- Start
- Apr 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of SAP003 in breast cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and 2 more (2 cohorts), sponsored by iNGENū CRO. Primary endpoints: Maximum tolerated dose of Sapu003 in combination with exemestane and Maximum tolerated dose of Sapu003 monotherapy. Started Apr 2026; status: recruiting.
02
Drugs
SAP003
03
Conditions
breast cancerrenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)apudoma (NET)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on ACTRN12625001083482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001083482.